BRPI0414030A - método para detectar desordens neoplásicas em uma amostra corporal solubilizada - Google Patents

método para detectar desordens neoplásicas em uma amostra corporal solubilizada

Info

Publication number
BRPI0414030A
BRPI0414030A BRPI0414030-3A BRPI0414030A BRPI0414030A BR PI0414030 A BRPI0414030 A BR PI0414030A BR PI0414030 A BRPI0414030 A BR PI0414030A BR PI0414030 A BRPI0414030 A BR PI0414030A
Authority
BR
Brazil
Prior art keywords
neoplastic disorders
body sample
solubilized
detecting neoplastic
well
Prior art date
Application number
BRPI0414030-3A
Other languages
English (en)
Inventor
Ruediger Ridder
Anja Reichert
Magnus Von Knebel Doeberitz
Matthias Herkert
Alexander Duwe
Rainer Hipfel
Peter Martin
Original Assignee
Mtm Lab Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mtm Lab Ag filed Critical Mtm Lab Ag
Publication of BRPI0414030A publication Critical patent/BRPI0414030A/pt
Publication of BRPI0414030B1 publication Critical patent/BRPI0414030B1/pt
Publication of BRPI0414030B8 publication Critical patent/BRPI0414030B8/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5755—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the uterine cervix, uterine corpus or endometrium
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/25—Chemistry: analytical and immunological testing including sample preparation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"MéTODO PARA DETECTAR DESORDEM NEOPLáSICAS EM UMA AMOSTRA CORPORAL SOLUBILIZADA". A presente invenção se refere a um método para diagnóstico precoce de desordens neoplásicas tais como cânceres, bem como seus estágios precursores, particularmente cânceres do trato respiratório, sistema urinário, trato reprodutivo, câncer associado com infecção por HPV ou câncer do trato anogenital, a partir de amostras solubilizadas. A invenção está também direcionada para kits de teste úteis para essa finalidade, bem como dispositivos de diagnóstico in vitro. O desenvolvimento desses kits e dispositivos de diagnóstico in vitro para a finalidade acima também é um aspecto da presente invenção.
BRPI0414030A 2003-08-25 2004-08-20 método para detectar desordens neoplásicas, dispositivos de diagnóstico in vitro, dispositivo híbrido de captura, uso de uma fase sólida, métodos para desenvolver kits e métodos para avaliação de diagnóstico de desordens neoplásicas BRPI0414030B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03103218A EP1507148B1 (en) 2003-08-25 2003-08-25 Method for detecting carcinomas in a solubilized cervical body sample
PCT/EP2004/051872 WO2005088311A1 (en) 2003-08-25 2004-08-20 Method for detecting neoplastic disorders in a solubilized body sample

Publications (3)

Publication Number Publication Date
BRPI0414030A true BRPI0414030A (pt) 2007-01-23
BRPI0414030B1 BRPI0414030B1 (pt) 2017-04-04
BRPI0414030B8 BRPI0414030B8 (pt) 2021-07-27

Family

ID=33560881

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0414030A BRPI0414030B8 (pt) 2003-08-25 2004-08-20 método para detectar desordens neoplásicas, dispositivos de diagnóstico in vitro, dispositivo híbrido de captura, uso de uma fase sólida, métodos para desenvolver kits e métodos para avaliação de diagnóstico de desordens neoplásicas

Country Status (13)

Country Link
US (1) US7932047B2 (pt)
EP (2) EP1507148B1 (pt)
JP (2) JP5619336B2 (pt)
CN (1) CN1836166B (pt)
AT (2) ATE289685T1 (pt)
AU (1) AU2004317284B2 (pt)
BR (1) BRPI0414030B8 (pt)
CA (1) CA2528490C (pt)
DE (2) DE60300339T2 (pt)
ES (1) ES2342535T3 (pt)
MX (1) MXPA05013903A (pt)
RU (1) RU2405158C2 (pt)
WO (2) WO2005088311A1 (pt)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7601497B2 (en) 2000-06-15 2009-10-13 Qiagen Gaithersburg, Inc. Detection of nucleic acids by target-specific hybrid capture method
EP1510820B1 (en) * 2003-08-25 2010-03-17 MTM Laboratories AG Method for detecting medically relevant conditions in a solubilized LBC sample
US7972776B2 (en) * 2005-11-15 2011-07-05 Oncohealth Corporation Protein chips for HPV detection
JP2009536958A (ja) 2006-05-11 2009-10-22 ベクトン・ディキンソン・アンド・カンパニー 細胞からのタンパク質抽出方法
US8968995B2 (en) 2008-11-12 2015-03-03 Oncohealth Corp. Detection, screening, and diagnosis of HPV-associated cancers
US8278056B2 (en) * 2008-06-13 2012-10-02 Oncohealth Corp. Detection of early stages and late stages HPV infection
WO2010129821A1 (en) * 2009-05-07 2010-11-11 Oncohealth Corporation Identification of high grade or ≥cin2 for early stages and late stages detection, screening, and diagnosis of human papillomavirus (hpv) and hpv-associated cancers
US9207240B2 (en) 2007-11-14 2015-12-08 Arbor Vita Corporation Method of efficient extraction of protein from cells
KR101711860B1 (ko) * 2008-01-25 2017-03-03 베르그 엘엘씨 발암성, 종양 진행 및 치료 효능을 평가하는 분석 시스템
US20090204009A1 (en) * 2008-02-07 2009-08-13 Los Alamos National Security Medical device system and related methods for diagnosing abnormal medical conditions based on in-vivo optical properties of tissue
EP2356460B1 (en) * 2008-09-04 2018-01-24 Ventana Medical Systems, Inc. Method for prediction of the progression risk of tumors
TWI419974B (zh) 2008-10-27 2013-12-21 Qiagen Gaithersburg Inc 於自動平台上之快速結果雜交捕捉法
CN101487845B (zh) * 2009-02-19 2013-01-02 苏州海路生物技术有限公司 大便标本自动检测仪
WO2010127228A1 (en) 2009-05-01 2010-11-04 Qiagen Gaithersburg, Inc. A non-target amplification method for detection of rna splice-forms in a sample
JP5819851B2 (ja) * 2010-01-08 2015-11-24 オンコヘルス コーポレーション Ｈｐｖ関連の癌の治療及びスクリーニングのための細胞に基づいた高処理能力ｈｐｖ免疫アッセイ
JP2013517803A (ja) 2010-01-29 2013-05-20 キアジェン ゲイサーズバーグ インコーポレイテッド サンプル中のｈｐｖの存在を決定および確認する方法
CA2787924A1 (en) 2010-01-29 2011-08-04 Qiagen Gaithersburg, Inc. Methods and compositions for sequence-specific purification and multiplex analysis of nucleic acids
EP2572001A2 (en) 2010-05-19 2013-03-27 QIAGEN Gaithersburg, Inc. Methods and compositions for sequence-specific purification and multiplex analysis of nucleic acids
JP6153866B2 (ja) 2010-05-25 2017-06-28 キアゲン ガイサーズバーグ アイエヌシー． 迅速なハイブリッド捕捉アッセイ、及び関連する戦略的に切断されたプローブ
WO2011158847A1 (ja) * 2010-06-17 2011-12-22 国立大学法人 岡山大学 microRNA標的遺伝子検出用キット及びmicroRNA標的遺伝子の検出方法
GB201014335D0 (en) * 2010-08-27 2010-10-13 Forensic Science Service Ltd Improvements in and relating to analysis
AU2011295715B9 (en) 2010-09-03 2017-02-23 Abbvie Stemcentrx Llc Novel modulators and methods of use
CN102033056B (zh) * 2010-10-14 2012-05-30 中国科学院化学研究所 抑制膜蛋白受体聚集的抗癌药物鉴定方法
WO2012116220A2 (en) 2011-02-24 2012-08-30 Qiagen Gaithersburg, Inc. Materials and methods for detection of hpv nucleic acid
AU2012340441A1 (en) * 2011-11-15 2014-05-29 University Of Miami Methods for detecting human papillomavirus and providing prognosis for head and neck squamous cell carcinoma
RU2508542C1 (ru) * 2012-07-16 2014-02-27 Полина Михайловна Шварцбурд Экспресс-способ определения риска злокачественности клеток
RU2535071C1 (ru) * 2013-04-09 2014-12-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Ивановская государственная медицинская академия" Министерства здравоохранения Российской Федерации Способ диагностики недифференцированной дисплазии соединительной ткани у женщин с потерей беременности в анамнезе
WO2015017692A1 (en) * 2013-07-31 2015-02-05 University Of Miami Compositions and methods for identifying a risk of cancer in a subject
WO2015147370A1 (en) * 2014-03-28 2015-10-01 Seegene, Inc. Detection of target nucleic acid sequences using different detection temperatures
RU2558987C1 (ru) * 2014-04-21 2015-08-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Самарский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ диагностики степени тяжести недифференцированной дисплазии соединительной ткани у женщин репродуктивного возраста
JP6854246B2 (ja) 2015-06-08 2021-04-07 アーケア ダイアグノスティクス リミテッド 尿サンプルの分析方法
EP3304084B1 (en) 2015-06-08 2022-03-23 Arquer Diagnostics Limited Methods and kits
CN106610434A (zh) * 2016-02-26 2017-05-03 弗雷米德生物医药技术（天津）有限公司 一种hpv16型e7蛋白的elisa检测试剂盒
RU2680930C2 (ru) * 2017-03-24 2019-02-28 федеральное государственное бюджетное образовательное учреждение высшего образования "Северный государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ забора материала для цитологического исследования при опухолевых заболеваниях поджелудочной железы, печени и желчевыводящих путей
CN107748265A (zh) * 2017-09-29 2018-03-02 中南大学湘雅医院 Cdc6和ki67在制备癌症放疗抵抗的诊断标记物中的应用
EP3732301A4 (en) * 2017-12-29 2022-02-09 Vertex Pharmaceuticals Incorporated METHOD OF TREATMENT OF CANCER USING AN ATR INHIBITOR
US11230729B2 (en) * 2018-04-20 2022-01-25 Inanna Diagnostics, Inc Methods and devices for obtaining cellular and DNA material from human female reproductive system
CN109781977B (zh) * 2019-01-09 2022-03-29 首都医科大学附属北京安定医院 IL15Rα以及相关膜蛋白检测试剂盒及其应用
RU2707099C1 (ru) * 2019-04-24 2019-11-22 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Петрова" Министерства здравоохранения Российской Федерации Способ скрининга злокачественных опухолей органов грудной полости
MX380106B (es) * 2019-05-21 2025-03-12 Timser S A P I De C V Biomarcadores relacionados a cancer.
CN117233382A (zh) * 2023-09-08 2023-12-15 江苏默乐生物科技股份有限公司 一种可同时检测低危型和高危型人乳头瘤病毒的抗原检测试剂盒及其应用
CN119639903B (zh) * 2025-01-17 2025-11-25 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 用于肝内胆管癌的生物标记物、药物及其应用
CN121208346B (zh) * 2025-11-25 2026-04-14 长兴固容生物科技有限公司 一种用于宫颈癌筛查、诊断的标志物组及其用途

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4281061A (en) * 1979-07-27 1981-07-28 Syva Company Double antibody for enhanced sensitivity in immunoassay
US5889169A (en) * 1991-05-16 1999-03-30 Cold Spring Harbor Laboratory Cell cycle regulatory protein p16 gene
EP0584264A1 (en) 1991-05-16 1994-03-02 Cold Spring Harbor Laboratory D-type cyclin and uses related thereto
EP0643836B1 (en) * 1991-12-13 1999-09-08 Bion Diagnostic Sciences, Inc. Agglutination assays and kits employing colloidal dyes
US6316208B1 (en) * 1994-01-07 2001-11-13 Memorial Sloan-Kettering Cancer Center Methods for determining isolated p27 protein levels and uses thereof
US6060301A (en) * 1994-03-18 2000-05-09 Myriad Genetics, Inc. Vector containing MTS1E1β gene
US5989815A (en) * 1994-03-18 1999-11-23 University Of Utah Research Foundation Methods for detecting predisposition to cancer at the MTS gene
CA2162150C (en) * 1994-03-18 2010-03-30 Mark H. Skolnick Germline mutations in the mts gene and method for detecting predisposition to cancer at the mts gene
CA2164167A1 (en) 1994-12-20 1996-06-21 Izak Bahar Assay normalization method
US6033847A (en) * 1995-02-06 2000-03-07 St. Jude Children's Research Hospital InK4c-p18 and InK4d-p19, inhibitors of cyclin-dependent kinases CDK4 and CDK6, and uses thereof
US5843756A (en) * 1995-06-07 1998-12-01 Myriad Genetics, Inc. Mouse MTSI gene
US6403383B1 (en) * 1996-03-11 2002-06-11 American Bio Medica Corp. Diagnostic test kit for immunological assays of fluid samples
US5976799A (en) * 1996-03-21 1999-11-02 The Board Of Trustees Of The University Of Arkansas Early detection of ovarian carcinoma using P16 gene products
US5955268A (en) * 1996-04-26 1999-09-21 Abbott Laboratories Method and reagent for detecting multiple nucleic acid sequences in a test sample
US5858683A (en) * 1996-08-30 1999-01-12 Matritech, Inc. Methods and compositions for the detection of cervical cancer
CA2289942C (en) * 1997-05-15 2009-05-05 Thomas Jefferson University Determination of cyclin-dependent kinase inhibitor p27 levels as a prognostic factor in cancer patients
AU8403098A (en) 1997-07-15 1999-02-10 Deaconess Hospital Reagents and methods for diagnosis and prognosis of proliferative disor ders
US6090579A (en) * 1997-08-12 2000-07-18 Smithkline Beecham Corporation Human SDR2 cDNA clone
CA2313641A1 (en) * 1997-12-12 1999-06-24 Digene Corporation Universal collection medium
US20010051364A1 (en) * 1997-12-23 2001-12-13 Francis Michon Procedures for the extraction and isolation of bacterial capsular polysaccharides for use as vaccines or linked to proteins as conjugate vaccines
US5994079A (en) * 1998-02-06 1999-11-30 Digene Corporation Direct detection of RNA mediated by reverse transcriptase lacking RNAse H function
US7399589B2 (en) * 1998-02-06 2008-07-15 Digene Corporation Immunological detection of RNA:DNA hybrids on microarrays
US6686151B1 (en) * 1998-02-06 2004-02-03 Digene Corporation Immunological detection of RNA:DNA hybrids on microarrays
US6576420B1 (en) * 1998-06-23 2003-06-10 Regents Of The University Of California Method for early diagnosis of, and determination of prognosis in, cancer
US7306926B2 (en) * 1998-07-01 2007-12-11 Mtm Laboratories Ag Method for detecting carcinomas in a solubilized cervical body sample
DE19829473C2 (de) * 1998-07-01 2000-08-10 Magnus Von Knebel Doeberitz Ch Verfahren zur frühen Diagnose von Carcinomen
US6593084B2 (en) * 1998-10-13 2003-07-15 Robert E. Bird Carcinogen assay
WO2000031538A1 (en) * 1998-11-23 2000-06-02 Praxsys Biosystems, Inc. Improved lateral flow assays
SE515668C2 (sv) * 1999-02-22 2001-09-17 Quantovir Ab Metod och kit för tidig förutsägelse av cancer
DE10014685B4 (de) * 2000-03-24 2004-07-01 Schubert, Walter, Dr. Verfahren zur Identifizierung von zellspezifischen Zielstrukturen
GB0018140D0 (en) 2000-07-24 2000-09-13 Medical Res Council Screening for abnormalities
DE10063179A1 (de) * 2000-12-18 2002-06-20 Bayer Ag Verfahren zur spezifischen Detektion von Tumorzellen und ihren Vorstufen in Gebärmutterhalsabstrichen durch simultane Messung von mindestens zwei verschiedenen molekularen Markern
ITRM20010363A1 (it) * 2001-06-25 2001-09-24 Franco Castelmani Gancio adattivo applicato ad un generatore di vivrazioni sinusoidali.
EP2267155B2 (en) * 2002-01-07 2016-09-07 Norchip A/S Method for detecting human papillomavirus mRNA
EP1333278B1 (en) * 2002-02-01 2004-03-10 MTM molecular tools in medicine Methods for monitoring and prognosis of disease course of gastrointestinal tumors
DE60200248T2 (de) 2002-08-01 2005-01-27 Mtm Laboratories Ag Verfahren für Lösung-basierte Diagnose
US7361460B2 (en) * 2003-04-11 2008-04-22 Digene Corporation Approach to molecular diagnosis of human papillomavirus-related diseases

Also Published As

Publication number Publication date
DE60300339D1 (de) 2005-03-31
WO2005084103A2 (en) 2005-09-15
JP5677270B2 (ja) 2015-02-25
HK1092219A1 (zh) 2007-02-02
AU2004317284B2 (en) 2009-11-05
ES2342535T3 (es) 2010-07-08
WO2005088311A1 (en) 2005-09-22
ATE289685T1 (de) 2005-03-15
DE60300339T2 (de) 2006-04-13
EP1507148B1 (en) 2005-02-23
JP2007503208A (ja) 2007-02-22
JP5619336B2 (ja) 2014-11-05
JP2012032412A (ja) 2012-02-16
CN1836166A (zh) 2006-09-20
DE602004026014D1 (de) 2010-04-29
BRPI0414030B8 (pt) 2021-07-27
RU2006101395A (ru) 2006-06-10
RU2405158C2 (ru) 2010-11-27
CA2528490C (en) 2015-11-03
EP1664788A1 (en) 2006-06-07
CN1836166B (zh) 2010-05-26
US20070190529A1 (en) 2007-08-16
ATE461449T1 (de) 2010-04-15
US7932047B2 (en) 2011-04-26
BRPI0414030B1 (pt) 2017-04-04
CA2528490A1 (en) 2005-09-22
MXPA05013903A (es) 2006-03-09
EP1507148A1 (en) 2005-02-16
AU2004317284A1 (en) 2005-09-22

Similar Documents

Publication Publication Date Title
BRPI0414030A (pt) método para detectar desordens neoplásicas em uma amostra corporal solubilizada
Lundberg et al. Elevated nitric oxide in the urinary bladder in infectious and noninfectious cystitis
NZ578283A (en) Proteomic profiling method useful for condition diagnosis and monitoring, composition screening, and therapeutic monitoring
BRPI0412725A (pt) marcadores para detecção de cáncer gástrico
EP1842065A4 (en) METHODS OF DIAGNOSIS AND PROGNOSIS OF EPITHELIAL CANCERS
BRPI0707645B8 (pt) métodos in vitro para detecção de câncer em um indivíduo e para avaliação de prognóstico de um indivíduo tendo, ou suspeito de ter, câncer ovariano
IN2015DN03125A (pt)
WO2006091412A3 (en) Adamts-7 as a biomarker for cancers of epithelial origin
DE69926630D1 (de) Antikörper gegen die ed-b domäne von fibronektin, solche antikörper enthaltende konjugate, und deren verwendung zur diagnose und therapie von angiogenese-assoziierten tumoren und krankheiten
ATE519865T1 (de) Verfahren zur diagnose und verfolgung von bakterieller vaginose mittels molekularer quantifizierung
AR003975A1 (es) Una preparacion farmaceutica para la deteccinn de una anormalidades del sistema nervioso central
WO2007136436A3 (en) Detection of anthrax pathogenicity factors
BR0317394A (pt) Uso de nicotinamida n-metiltransferase como um marcador para câncer colorretal
WO2023004083A3 (en) Compositions and methods for detection of bile duct cancer
FR2919061B1 (fr) Procede de dosage de la plastine-i pour le diagnostic in vitro du cancer colorectal.
BRPI0315735A8 (pt) método para o ensaio de ngf a diagnose in vitro de câncer de mama e uso terapêutico
ATE429440T1 (de) Formen prostataspezifischer antigene und verfahren zu deren nachweis
MX2024004843A (es) Sustrato enzimatico fret y usos del mismo en el cancer de higado.
JIANG et al. Research progress of chemiluminescence probes based on adamantane-dioxetane
DE602006018458D1 (de) Antikörper gegen histonmodifikationen für die klinische krebsdiagnose und -prognose
MX2025007666A (es) Compuesto - marcador de diagnostico de cancer de vias biliares, metodo para detectar la actividad enzimatica, metodo para el diagnostico de cancer de vias biliares, kit que comprende el compuesto, usos del compuesto y metodo para el tratamiento de cancer de vias biliares
MX2024015380A (es) Compuesto y marcador de diagnostico para el cancer de cuerpo uterino, metodo para detectar la actividad enzimatica, metodo para el diagnostico del cancer de cuerpo uterino, kit que comprende el compuesto, usos del compuesto y metodo para el tratamiento del cancer de cuerpo uterino
MXPA05006765A (es) Procedimiento de deteccion de prp utilizando un antibiotico de aminoglicosidos.
MX2025009077A (es) Compuesto, marcador de diagnostico para cancer de estomago, metodo de deteccion de actividad enzimatica, metodo de diagnostico de cancer de estomago, kit que comprende dicho compuesto, usos del compuesto y metodo para el tratamiento del cancer de estomago
MX2025003506A (es) Compuesto - marcador para diagnostico de cancer de ovario, metodo para detectar actividad enzimatica, metodo para el diagnostico de cancer de ovario, kit que comprende el compuesto, usos del compuesto y metodo para el tratamiento de cancer de ovario

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07B Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette]

Free format text: REF. A RPI NO 2389 DE 18/10/2016.

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B25D Requested change of name of applicant approved

Owner name: ROCHE MTM LABORATORIES AG (DE)

B25G Requested change of headquarter approved

Owner name: ROCHE MTM LABORATORIES AG (DE)

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B25A Requested transfer of rights approved
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/08/2004, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B21H Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2846 DE 22/07/2025 POR TER SIDO INDEVIDA.